Structure via PubChem · Public domain (PubChem)
trifluridine
Sign in to saveAlso known as THE694, TFT, trifluorothymidine, 5-(Trifluoromethyl)deoxyuridine, 5-Trifluoromethyl-2-deoxyuridine, Trifluoromethyldeoxyuridine, trifluorothymine deoxyriboside
Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals.
Chemical data
- Formula
- C10H11F3N2O5
- Molecular weight
- 296.2 g/mol
- IUPAC name
- 1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
- SMILES
- C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
- InChIKey
- VSQQQLOSPVPRAZ-RRKCRQDMSA-N
- XLogP
- -0.5
- Polar surface area
- 99.1 Ų
- H-bond donors
- 3
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1980
- Admin. routes
- oral, topical
- Indications
- neoplasm, colorectal adenocarcinoma, rectum cancer, colorectal carcinoma
via ChEMBL · EBI
Research
1,218 papers- Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.The Lancet. Oncology · 2018
- Trifluridine/tipiracil in the treatment of gastric cancer.Future oncology (London, England) · 2022
- Trifluridine/tipiracil (FTD/TPI) and regorafenib in older patients with metastatic colorectal cancer.Journal of geriatric oncology · 2023
- Trifluridine/tipiracil for the treatment of metastatic gastric cancer.Expert review of gastroenterology & hepatology · 2020
- Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.Future oncology (London, England) · 2018
via PubMed
Wikidata facts
- Subclass of
- nucleoside analogue
- Mass
- 296.062006
- Has use
- medication
Show 6 more facts
- subject has role
- antimetabolite
- chemical formula
- C₁₀H₁₁F₃N₂O₅
- Commons category
- Trifluridine
- canonical SMILES
- C1C(C(OC1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
- isomeric SMILES
- C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)C(F)(F)F)CO)O
- World Health Organisation international non-proprietary name
- trifluridine
via Wikidata · CC0
~4 min read
Encyclopedic overview
10 sectionsContents
- Medical uses
- Adverse effects
- Interactions
- Pharmacology
- Mechanism of action (eye drops)
- Pharmacokinetics (eye drops)
- Pharmacokinetics (oral)
- Chemistry
- References
- External links
Trifluridine (also called trifluorothymidine; abbreviation TFT or FTD) is an anti-herpesvirus antiviral drug, used primarily as prescription eyedrops. It was sold under the trade name Viroptic by Glaxo Wellcome, now merged into GlaxoSmithKline. The brand is now wholly owned by King Pharmaceuticals.
Trifluridine was approved for medical use in 1980. It is also a component of the anti-cancer drug trifluridine/tipiracil, which is taken by mouth.
Excerpted from Wikipedia’s “trifluridine” article, available under the CC BY-SA 4.0 licence.